Low-dose nano-gel incorporated with bile acids enhanced pharmacology of surgical implants
Aim: Major challenges to islet transplantation in Type 1 diabetes include host-inflammation, which results in failure to maintain survival and functions of transplanted islets. Therefore, this study investigated the applications of encapsulating the bile acid ursodeoxycholic acid (UDCA) with transplanted islets within improved nano-gel systems for Type 1 diabetes treatment. Materials & methods: Islets were harvested from healthy mice, encapsulated using UDCA-nano gel and transplanted into the diabetic mice, while the control group was transplanted encapsulated islets without UDCA. The two groups' survival plot, blood glucose, and inflammation and bile acid profiles were analyzed. Results & conclusion: UDCA-nano gel enhanced survival, glycemia and normalized bile acids' profile, which suggests improved islets functions and potential adjunct treatment for insulin therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 14(2023), 1 vom: 01. Jan., Seite 17-29 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mooranian, Armin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bile Acids and Salts |
|---|
| Anmerkungen: |
Date Completed 05.04.2023 Date Revised 10.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2022-0037 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354252372 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354252372 | ||
| 003 | DE-627 | ||
| 005 | 20231226061819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2022-0037 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354252372 | ||
| 035 | |a (NLM)36919692 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mooranian, Armin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low-dose nano-gel incorporated with bile acids enhanced pharmacology of surgical implants |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2023 | ||
| 500 | |a Date Revised 10.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Major challenges to islet transplantation in Type 1 diabetes include host-inflammation, which results in failure to maintain survival and functions of transplanted islets. Therefore, this study investigated the applications of encapsulating the bile acid ursodeoxycholic acid (UDCA) with transplanted islets within improved nano-gel systems for Type 1 diabetes treatment. Materials & methods: Islets were harvested from healthy mice, encapsulated using UDCA-nano gel and transplanted into the diabetic mice, while the control group was transplanted encapsulated islets without UDCA. The two groups' survival plot, blood glucose, and inflammation and bile acid profiles were analyzed. Results & conclusion: UDCA-nano gel enhanced survival, glycemia and normalized bile acids' profile, which suggests improved islets functions and potential adjunct treatment for insulin therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a bile acids | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a graft | |
| 650 | 4 | |a nano gel | |
| 650 | 4 | |a pharmaceutical sciences | |
| 650 | 4 | |a surfactant | |
| 650 | 4 | |a transplantation | |
| 650 | 7 | |a Bile Acids and Salts |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Ionescu, Corina Mihaela |e verfasserin |4 aut | |
| 700 | 1 | |a Wagle, Susbin Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacevic, Bozica |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Chester, Jacqueline |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Edan |e verfasserin |4 aut | |
| 700 | 1 | |a Mikov, Momir |e verfasserin |4 aut | |
| 700 | 1 | |a Stankov, Karmen |e verfasserin |4 aut | |
| 700 | 1 | |a Elnashar, Magdy |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Salami, Hani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 14(2023), 1 vom: 01. Jan., Seite 17-29 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:17-29 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2022-0037 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 01 |c 01 |h 17-29 | ||